XNCR carries one of the more stubborn short positions in small-cap biotech into Thursday's Q1 2026 report — and the lending market says the bears have plenty of capacity left to press.
Short interest is running at 14.3% of the free float, backed by roughly 10.2 million shares short. That level has been remarkably stable over the past two weeks, barely moving despite an 12% price rally over the same period. What's more telling is the direction of travel over the past month: SI dropped about 10% from mid-April highs near 11.4 million shares, suggesting some covering as the stock climbed. Borrow cost has eased to 0.46% — a low reading that signals borrowing remains cheap. Availability is ample, meaning there is no squeeze pressure in the lending pool ahead of the print.
Options tell a different story than the short book. The put/call ratio has actually eased from elevated levels. It now stands at 1.46, well below its 20-day average of 1.88 and nearly a full standard deviation below the mean. In late April, PCR was pushing 2.5, close to its 52-week high of 3.43. The sharp drop in put demand is notable: options traders who were heavily defensive through April have pulled back on protection heading into the announcement. With a short score of 70.3 — ranking in the 90th percentile — ORTEX flags this name as one of the more heavily monitored shorts in the universe, yet the immediate borrow and options signals point to less urgency than they did three weeks ago.
The analyst debate cuts to the heart of the company's pipeline risk. Bulls point to the XmAb technology platform and the commercial ramp in partnership revenues from Ultomiris and Monjuvi, alongside early encouraging data from XmAb819. EPS momentum over the past 90 days ranks at the 83rd percentile — above the pack for a biotech burning cash. The analyst consensus leans buy, with five positive ratings and a mean price target around $28, implying a return potential of over 120% from current levels. But that optimism must be weighed carefully: JPMorgan downgraded XNCR to Neutral in late March, cutting its target to $13 — almost exactly where the stock trades today. That's a pointed signal from a bellwether firm. Bears focus on documented dosing errors in clinical trials, elevated cytokine release syndrome rates, and the risk that pipeline assets get discounted to near-cash value if partnership timelines slip. The stock is down 13% year-to-date, reflecting how seriously the market is taking those concerns.
Institutional ownership adds an interesting layer. RA Capital Management entered the top holders with a fresh 4.7 million share position as of late March — a full new stake, not an add. BVF Partners, a specialist life sciences manager, holds nearly 10% of shares outstanding. These are not passive holders; their presence signals conviction on the long side from investors who do the clinical diligence. The last two earnings prints also carry weight: Q4 2025 produced a 14.7% one-day gain, followed by a 7.9% five-day return; Q3 2025 went the other way, with a 3.3% drop and a 2.6% five-day decline. The reaction history is asymmetric — big moves in both directions are on the table.
Thursday's print will test whether Xencor can demonstrate enough pipeline progress and partnership revenue clarity to justify anything above the $13 floor that JPMorgan just drew.
See the live data behind this article on ORTEX.
Open XNCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
